ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in
kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor
prognosis. TGFa and EGF, the ligands for EGFR, are also overexpressed in some of these tumor
types, suggesting a self-propagating stimulus that may be responsible for rapid tumor growth.
Blocking this stimulus by blocking activation of EGFR with ABX-EGF, a fully human monoclonal
antibody against EGFR, may prevent tumor growth and perhaps shrink tumors. Purpose: This is a
Phase 2 clinical trial to evaluate the safety and efficacy of ABX-EGF in the treatment of
advanced NSCLC following failure of paclitaxel and carboplatin therapy on treatment arm 1 of
Immunex Protocol 054.0004 (Amgen Protocol 20025404), Part 2.